Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

(2017) David Miles et al.   EUROPEAN JOURNAL OF CANCER

Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy

(2016) Ivana Vidlickova et al.   BMC CANCER

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer

(2016) Z. A. Nahleh et al.   BREAST CANCER RESEARCH AND TREATMENT

Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy

(2016) S. W. Lam et al.   CLINICAL CANCER RESEARCH

Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer

(2016) Ursa Brown-Glaberman et al.   DISEASE MARKERS

Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer

(2015) Helga Helseth Hektoen et al.   BMC CANCER

Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic

(2015) Ace J. Hatch et al.   CANCER JOURNAL

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study

(2015) Alexander Hein et al.   INTERNATIONAL JOURNAL OF CANCER

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial

(2015) Helena M Earl et al.   LANCET ONCOLOGY

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

(2015) Harry D Bear et al.   LANCET ONCOLOGY

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial

(2015) Karim Chamie et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)†

(2014) G. von Minckwitz et al.   ANNALS OF ONCOLOGY

Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline

(2014) Naoki Aomatsu et al.   BMC CANCER

Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor–Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer

(2014) Grant D. Stewart et al.   EUROPEAN UROLOGY

Prognostic Value of Carbonic Anhydrase IX Immunohistochemical Expression in Renal Cell Carcinoma: A Meta-Analysis of the Literature

(2014) Zhihong Zhao et al.   PLoS One

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

(2013) D W Miles et al.   BRITISH JOURNAL OF CANCER

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44)

(2013) Jens Huober et al.   EUROPEAN JOURNAL OF CANCER

Relevance of cellular and serum carbonic anhydrase IX in primary breast cancer

(2013) Dina Schütze et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer

(2013) Jonathan Welti et al.   JOURNAL OF CLINICAL INVESTIGATION

Markers of Response for the Antiangiogenic Agent Bevacizumab

(2013) Diether Lambrechts et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-VEGF Therapies in the Clinic

(2013) K. L. Meadows et al.   Cold Spring Harbor Perspectives in Medicine

SnapShot: Tumor Angiogenesis

(2012) Rakesh K. Jain et al.   CELL

Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy

(2012) A. McIntyre et al.   CLINICAL CANCER RESEARCH

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy

(2012) Nehmat Houssami et al.   EUROPEAN JOURNAL OF CANCER

Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting

(2012) Lisa M. McShane et al.   JOURNAL OF CLINICAL ONCOLOGY

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

(2012) Michael Untch et al.   LANCET ONCOLOGY

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

(2012) Diether Lambrechts et al.   LANCET ONCOLOGY

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

(2012) Harry D. Bear et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma

(2012) MARTINA TAKACOVA et al.   Oncology Letters

Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer

(2011) Linn Woelber et al.   BMC CANCER

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer

(2010) M İlie et al.   BRITISH JOURNAL OF CANCER

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2010) C. Pena et al.   CLINICAL CANCER RESEARCH

Serum carbonic anhydrase IX during first-line therapy of ovarian cancer

(2010) Linn Woelber et al.   GYNECOLOGIC ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation

(2010) P Swietach et al.   ONCOGENE

Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited

(2009) Sonja Loges et al.   CANCER CELL